Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,956 questions in 143 reviews · Musculoskeletal
current versionsNo studies 555 · 28.4%Ungraded 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Resistance training vs flexibility exercise All‐cause attrition Dropout rates · Individuals with fibromyalgia. Resistance exercise training for fibromyalgia (2013) · Cochrane | RR 1 [0.37, 2.73] | 1 study · 56 participants | Low |
Resistance training vs control Self reported physical function Health Assessment Questionnaire and SF‐36 Physical Function Score Scale 0‐100 (converted so lower scores indicate better health) · Individuals with fibromyalgia. Resistance exercise training for fibromyalgia (2013) · Cochrane | no estimate extracted | 3 studies · 107 participants | Low |
Resistance training vs control Pain Visual analog scale Scale 0‐10 cm (lower scores indicate less pain) · Individuals with fibromyalgia. Resistance exercise training for fibromyalgia (2013) · Cochrane | no estimate extracted | 2 studies · 81 participants | Low |
Resistance training vs control Tenderness Tender point count and myalgic scores Scores converted to tender points, 0‐18 (lower scores indicate less tenderness) · Individuals with fibromyalgia. Resistance exercise training for fibromyalgia (2013) · Cochrane | no estimate extracted | 3 studies · 107 participants | Low |
Resistance training vs control Muscle strength Maximum concentric leg extension (load measured in kg). · Individuals with fibromyalgia. Resistance exercise training for fibromyalgia (2013) · Cochrane | no estimate extracted | 2 studies · 47 participants | Low |
Resistance training vs control Adverse effects · Individuals with fibromyalgia. Resistance exercise training for fibromyalgia (2013) · Cochrane | no estimate extracted | NR | No studies |
Resistance training vs control All‐cause attrition Dropout rates. · Individuals with fibromyalgia. Resistance exercise training for fibromyalgia (2013) · Cochrane | RR 3.5 [0.79, 15.49] | 3 studies · 107 participants | Low |
Resistance training vs aerobic training Multidimensional function FIQ Total Score. Scale 0‐100 (lower scores indicate greater health) · Individuals with fibromyalgia. Resistance exercise training for fibromyalgia (2013) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
Resistance training vs aerobic training Self reported physical function SF‐36 Physical Function Scale. Scale 0‐100 (higher scores indicate greater health) · Individuals with fibromyalgia. Resistance exercise training for fibromyalgia (2013) · Cochrane | no estimate extracted | 2 studies · 86 participants | Low |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Arthroplasty instability ‐ inferred from roentgen stereophotogrammetric analysis (Available data analysis) · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | RR 0.47 [0.24, 0.92] | 3 studies · 216 participants | Moderate |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Survival rate of the implant (any change of a component) · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Global Assessment (Patient) · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 1 study · 27 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Functional measures with validated instruments · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 4 studies · 240 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Pain · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Health‐related quality of life measures · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Total adverse event · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Pain 10‐cm VAS scale (median · participants with osteoarthritis of the knee or hip Doxycycline for osteoarthritis of the knee or hip (2012) · Cochrane | no estimate extracted | 2 studies · 524 participants | Moderate |
Intervention NR Function WOMAC function (range 0 to 10) (median · participants with osteoarthritis of the knee or hip Doxycycline for osteoarthritis of the knee or hip (2012) · Cochrane | no estimate extracted | 2 studies · 517 participants | Moderate |
Intervention NR Minimum joint space width ( · participants with osteoarthritis of the knee or hip Doxycycline for osteoarthritis of the knee or hip (2012) · Cochrane | no estimate extracted | 1 study · 361 participants | Moderate |
Intervention NR Number of participants experiencing any adverse event ( · participants with osteoarthritis of the knee or hip Doxycycline for osteoarthritis of the knee or hip (2012) · Cochrane | RR 1.36 [1.08, 1.72] | 1 study · 232 participants | Low |
Intervention NR Number of participants withdrawn due to adverse events (median · participants with osteoarthritis of the knee or hip Doxycycline for osteoarthritis of the knee or hip (2012) · Cochrane | RR 2.28 [1.06, 4.9] | 2 studies · 663 participants | Low |
Intervention NR Number of participants experiencing any serious adverse event (median · participants with osteoarthritis of the knee or hip Doxycycline for osteoarthritis of the knee or hip (2012) · Cochrane | RR 1.07 [0.68, 1.68] | 2 studies · 663 participants | Low |
Febuxostat 40 mg/day vs placebo Incidence of gout flares · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 0.95 [0.52, 1.7] | 1 study · 75 participants | Low |
Febuxostat 80 mg/day vs placebo Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs placebo Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs placebo Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs placebo Serious Adverse Events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 2.8 [0.72, 10.7] | 2 studies · 479 participants | Moderate |
Febuxostat 80 mg/day vs placebo Discontinuations due to adverse events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.8 [0.74, 4.5] | 2 studies · 479 participants | Moderate |
Febuxostat 120 mg/day vs placebo Incidence of gout flares · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.7 [1.3, 2.3] | 2 studies · 479 participants | Moderate |
Febuxostat 120 mg/day vs placebo Serum uric acid <6.0 mg/dL at final visit · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | RR 80.7 [16, 405.5] | 2 studies · 356 participants | Low |
Febuxostat 120 mg/day vs placebo Pain · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs placebo Patient global assessment · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 120 mg/day vs placebo Health Related Quality of Life · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs placebo Serum uric acid <6.0 mg/dL at final visit · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 40.1 [2.5, 639.1] | 1 study · 69 participants | Low |
Febuxostat 120 mg/day vs placebo Serious Adverse events · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | RR 2.7 [0.7, 10.2] | 2 studies · 479 participants | Moderate |
Febuxostat 120 mg/day vs placebo Discontinuations due to adverse events · patients with chronic cout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.7 [0.67, 4.1] | 2 studies · 479 participants | Moderate |
Febuxostat 40 mg/day vs allopurinol Incidence of gout flares · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 0.97 [0.57, 1.65] | 1 study · 1324 participants | High |
Febuxostat 40 mg/day vs allopurinol Serum uric acid <6.0 mg/dL at final visit · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.1 [0.94, 1.2] | 1 study · 1324 participants | Moderate |
Febuxostat 40 mg/day vs allopurinol Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs allopurinol Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs allopurinol Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 40 mg/day vs allopurinol Serious Adverse Events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 0.61 [0.35, 1.07] | 1 study · 1513 participants | High |
Febuxostat 40 mg/day vs allopurinol Discontinuations due to adverse events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.2 [0.9, 1.7] | 1 study · 1513 participants | High |
Febuxostat 80 mg/day vs allopurinol Incidence of gout flares · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.1 [0.98, 1.3] | 3 studies · 2325 participants | High |
Febuxostat 40 mg/day vs placebo Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Serum uric acid <6.0 mg/dL at final visit · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 1.8 [1.6, 2.2] | 3 studies · 2193 participants | Low |
Febuxostat 80 mg/day vs allopurinol Pain · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Patient global assessment · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Health Related Quality of Life · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | no estimate extracted | NR | No studies |
Febuxostat 80 mg/day vs allopurinol Serious Adverse Events · patients with chronic gout Febuxostat for treating chronic gout (2012) · Cochrane | RR 0.91 [0.34, 2.4] | 3 studies · 1044 participants | Moderate |